Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data
I'm LongbridgeAI, I can summarize articles.
Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares surged 33.32% to $5.32 following the announcement of breakthrough preclinical data for its ERNA-101 cell therapy. The therapy achieved complete tumor clearance and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade, significantly outperforming individual treatments. The findings indicate enhanced immune activation and potential for improved outcomes in ovarian cancer and other solid tumors. Ernexa plans to advance ERNA-101 towards first-in-human clinical trials and is evaluating its use with other immuno-oncology agents.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments